{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:17:34Z","timestamp":1786119454019,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1097\/mlr.0b013e3181d59541","type":"journal-article","created":{"date-parts":[[2010,5,14]],"date-time":"2010-05-14T03:40:58Z","timestamp":1273808458000},"page":"S83-S89","source":"Crossref","is-referenced-by-count":27,"title":["Privacy-Maintaining Propensity Score-Based Pooling of Multiple Databases Applied to a Study of Biologics"],"prefix":"10.1097","volume":"48","author":[{"given":"Jeremy A.","family":"Rassen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Herrinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20210211","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1002\/pds.1675","article-title":"A distributed research network model for post-marketing safety studies: the Meningococcal Vaccine Study.","volume":"17","author":"Velentgas","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R2-14-20210211","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/aje\/kwj127","article-title":"Methods for pooling results of epidemiologic studies: the Pooling Project of Prospective Studies of Diet and Cancer.","volume":"163","author":"Smith-Warner","year":"2006","journal-title":"Am J Epidemiol"},{"key":"R3-14-20210211","first-page":"335","article-title":"Confounding by indication.","volume":"7","author":"Walker","year":"1994","journal-title":"Epidemiology"},{"key":"R4-14-20210211","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/pds.607","article-title":"Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on Therapeutics.","volume":"10","author":"Platt","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R5-14-20210211","article-title":"Modern Epidemiology.","author":"Rothman","year":"2008"},{"key":"R6-14-20210211","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R8-14-20210211","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects.","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"R9-14-20210211","doi-asserted-by":"crossref","first-page":"757","DOI":"10.7326\/0003-4819-127-8_Part_2-199710151-00064","article-title":"Estimating causal effects from large data sets using propensity scores.","volume":"127","author":"Rubin","year":"1997","journal-title":"Ann Intern Med"},{"issue":"suppl 1","key":"R10-14-20210211","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1097\/MLR.0b013e3181d59541","article-title":"Privacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologics.","volume":"48","author":"Rassen","year":"2010","journal-title":"Med Care"},{"key":"R11-14-20210211","doi-asserted-by":"crossref","DOI":"10.1002\/0471722146","article-title":"Applied Logistic Regression.","author":"Hosmer","year":"2000"},{"key":"R12-14-20210211","article-title":"Categorical Data Analysis.","author":"Agresti","year":"1990"},{"key":"R13-14-20210211","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2307\/2532304","article-title":"Estimating exposure effects by modelling the expectation of exposure conditional on confounders.","volume":"48","author":"Robins","year":"1992","journal-title":"Biometrics"},{"key":"R14-14-20210211","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1742-7843.2006.pto_293.x","article-title":"Indications for propensity scores and review of their use in pharmacoepidemiology.","volume":"98","author":"Glynn","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R15-14-20210211","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/pds.1845","article-title":"Confounder summary scores when comparing the effects of multiple drug exposures.","volume":"19","author":"Cadarette","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R16-14-20210211","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R17-14-20210211","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs.","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"key":"R18-14-20210211","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1161\/CIRCULATIONAHA.109.873497","article-title":"Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome.","volume":"120","author":"Rassen","year":"2009","journal-title":"Circulation"},{"key":"R19-14-20210211","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","article-title":"Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.","volume":"51","author":"Gilard","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R20-14-20210211","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2009.261","article-title":"Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.","volume":"301","author":"Ho","year":"2009","journal-title":"JAMA"},{"key":"R21-14-20210211","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1503\/cmaj.082001","article-title":"A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.","volume":"180","author":"Juurlink","year":"2009","journal-title":"CMAJ"},{"key":"R22-14-20210211","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","article-title":"High-dimensional propensity score adjustment in studies of treatment effects using health care claims data.","volume":"20","author":"Schneeweiss","year":"2009","journal-title":"Epidemiology"}],"container-title":["Medical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MLR.0b013e3181d59541","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:20:21Z","timestamp":1786040421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005650-201006001-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/mlr.0b013e3181d59541","relation":{},"ISSN":["0025-7079"],"issn-type":[{"value":"0025-7079","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}